Alnylam Pharmaceutical’s has secured US Food and Drug Administration (FDA) approval for Amvuttra (vutrisiran), expanding its use to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare ...

Amvuttra now enters a potentially lucrative field largely dominated by Pfizer, whose Vyndaqel (tafamidis) family of transthyretin (TTR) stabilizer drugs won their initial ATTR-CM nods from the FDA ...

Amvuttra (vutrisiran) has become the first RNA interference therapy to be approved for ATTR-CM, and the second challenger to Pfizer's Vyndaqel/Vyndamax (tafamidis) – which became the first drug ...

The FDA has approved Alynylam’s RNAi therapy Amvuttra for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it to compete with Pfizer’s Vyndamax and BridgeBio’s Attruby.

setting it up to compete with therapies from BridgeBio and Pfizer. Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Vutrisiran (Amvuttra), a small-interfering RNA (siRNA) therapy, is now the third drug approved by the US Food and Drug Administration for the treatment of adults with transthyretin amyloid ...

Amvuttra is entering the ATTR cardiomyopathy market behind products from Pfizer that have become the standard of care and a BridgeBio Pharma drug approved last fall. But Amvuttra introduces a new ...

The ATTR-CM market has grown more competitive following Food and Drug Administration approval of BridgeBio's Attruby in November 2024. There is also competition from Pfizer's Vyndaqel and Vyndamax ...

Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...

Its drug will compete in the market for transthyretin amyloid cardiomyopathy (ATTR-CM) treatments ... causing protein at the source, unlike Pfizer's Vyndaqel and BridgeBio's (BBIO.O), opens ...

The ATTR-CM market is currently dominated by Pfizer’s Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s recently approved Attruby (acoramidis). Unlike these medications, which are TTR stabilisers ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.